New Result Shows High Therapeutic Benefits For Boehringer Ingelheim' Mirapexin/Sifrol
Study supports data from previous trial that demonstrated efficacy, safety and tolerability
Boehringer Ingelheim presented new data at the Movement Disorder Society’s 13th International Congress of Parkinson’s Disease and Movement Disorders (MDS). The new results confirms high therapeutic benefit of Mirapexin/Sifrol (pramipexole) once-daily, extended release formulation.
The study supports data from a previous trial that demonstrated the efficacy, safety and tolerability of the once daily formulation in the treatment of early PD at 18 weeks, and non-inferiority between pramipexole extended release and pramipexole immediate release at 33 weeks.
The randomised, placebo-controlled trial assessed the efficacy and safety of a once-daily, extended release formulation of pramipexole (administered as adjunctive therapy in advanced PD) compared to its immediate formulation when administered under the same therapeutic conditions. Both the primary and the key secondary endpoints were met in the study as measured by the change from baseline in UPDRS II+III and percentage of off-time during waking hours.
Related Insight
Suppliers Directory
Modgraph Consultants - Chemistry, Cheminformatics and Molecular Modeling Software Solutions
Modgraph Consultants Ltd. is an international software company specialising in the pharmaceutical industry, offering software solutions in chemistry, cheminformatics and molecular modeling.
Suppliers
GOEBEL Instrumentelle Analytik - Complete Solutions in HPLC and UV/VIS Spectrophotometry
GOEBEL Instrumentelle Analytik offers complete solutions in HPLC and UV/VIS Spectrophotometry.
Suppliers
Molecular Devices - Basic Life Science and Drug Discovery Research
Understanding your laboratory workflow is Molecular Devices' top priority, and we direct our product development efforts toward solving your unique issues.
Suppliers
Optima Group pharma - Filling and Packaging Machines for Syringes, Vials, Bottles and Carpules Products
Optima Group Pharma consists of four top-quality brands: Inova, Klee, Kugler and Metall + Plastic. Thanks to years of specializing, the Optima Group Pharma offers a comprehensive, cutting-edge range of products. This includes the filling and packaging of pharmaceutical liquids and powders, combined production and packaging lines for medical/ pharmaceutical products as well as automation and laboratory processes. Additionally the designing, manufacturing, installation and validation of state-of-the-art isolation and containment technology are also part of the portfolio.
Suppliers
Production & Manufacturing
Fine & Speciality Chemicals
Manufacturing
Process & Production
OTC
Drug Research Drug Delivery Drug Discovery & Development
Contract Research & Services Clinical Trials Contract Research Contract Services
Automation IT & Software Laboratory Instrumentation
Inward Investment Packaging Regulatory Affairs
Drug Research Drug Delivery Drug Discovery & Development
Contract Research & Services Clinical Trials Contract Research Contract Services
Automation IT & Software Laboratory Instrumentation
Inward Investment Packaging Regulatory Affairs
Intelligence
Best Practice Clinical Trial Pricing Using Benchmark Data
Published by Medidata Solutions
White Papers
MyQUMAS 2011
Published by QUMAS
White Papers
Contamination Concerns
Published by Phage Consultants
White Papers
Internet usage of Indian General Practitioners
Published by Kinapse
White Papers
Buy the latest industry research online today!
Nanotechnology in Drug Delivery - Technological Improvements and Novel Approaches to Fulfill High Potential
GBI Research, the leading business intelligence provider, has released its latest report, “Nanotechnology in Drug Delivery - Technological Improvements and Novel Approaches to Fulfill High Potential” that provides key data, information and analysis of the major trends and issues affecting the global nano-enabled drug delivery market. The report provides a comprehensive insight into the current and future application of nanotechnology in the drug delivery systems. It also provides an insight into the key drivers and barriers for the market growth. The report also provides a detailed analysis of the trends and its effects on the nano-enabled drug delivery market. The report also talks about the key regulations that affect the nanotechnology research and development and issues related to its use in pharmaceutical market. The report also details some case study of the latest technology being exploited in pharmaceutical industry. The report also provides detailed analysis of major deals that have happened in the nano-enabled drug delivery market landscape. At the end, the report looks into the future players. This report is built using data and information sourced from proprietary databases, primary and secondary research and in house analysis by GBI Research’s team of industry experts. The nano-enabled drug delivery market has been a high growth market and expected to grow at a faster rate in the near future. According to a study conducted by Willi Paul, and Chandra P. Sharma, the nano-enabled drug delivery market was $1.7 billion in 2009 and expected to reach over $4.8 billion in 2012. The market will witness increased competition, high investment from venture capitalist and government. The M&A and Licensing landscape will see significant changes in the coming future. This is because market is expected to become more lucrative in coming future. The major drivers for the market growth are Increasing acceptance of nano-enabled drugs, and a strong pipeline portfolio. The increasing governmental funding and R&D interest will strengthen the market in future. However, lack of consistent policy on technology transfer, poor R&D facility, and tight audit control and lack of centralized system will restrain the market growth. The nano-enabled drug delivery market has strong pipeline. The pipeline is primarily dominated by molecules in early stage of development. This suggests that the there is high level of R&D investment. This will support the future market and will fuel the licensing activity. Reports Buy online from $3500
GBI Research, the leading business intelligence provider, has released its latest report, “Nanotechnology in Drug Delivery - Technological Improvements and Novel Approaches to Fulfill High Potential” that provides key data, information and analysis of the major trends and issues affecting the global nano-enabled drug delivery market. The report provides a comprehensive insight into the current and future application of nanotechnology in the drug delivery systems. It also provides an insight into the key drivers and barriers for the market growth. The report also provides a detailed analysis of the trends and its effects on the nano-enabled drug delivery market. The report also talks about the key regulations that affect the nanotechnology research and development and issues related to its use in pharmaceutical market. The report also details some case study of the latest technology being exploited in pharmaceutical industry. The report also provides detailed analysis of major deals that have happened in the nano-enabled drug delivery market landscape. At the end, the report looks into the future players. This report is built using data and information sourced from proprietary databases, primary and secondary research and in house analysis by GBI Research’s team of industry experts. The nano-enabled drug delivery market has been a high growth market and expected to grow at a faster rate in the near future. According to a study conducted by Willi Paul, and Chandra P. Sharma, the nano-enabled drug delivery market was $1.7 billion in 2009 and expected to reach over $4.8 billion in 2012. The market will witness increased competition, high investment from venture capitalist and government. The M&A and Licensing landscape will see significant changes in the coming future. This is because market is expected to become more lucrative in coming future. The major drivers for the market growth are Increasing acceptance of nano-enabled drugs, and a strong pipeline portfolio. The increasing governmental funding and R&D interest will strengthen the market in future. However, lack of consistent policy on technology transfer, poor R&D facility, and tight audit control and lack of centralized system will restrain the market growth. The nano-enabled drug delivery market has strong pipeline. The pipeline is primarily dominated by molecules in early stage of development. This suggests that the there is high level of R&D investment. This will support the future market and will fuel the licensing activity. Reports Buy online from $3500
Comments may be moderated for spam, obscenities or defamation.